PDCD1 and hepatocellular carcinoma: Pembrolizumab is a humanized monoclonal antibody against PD-1 and when combined with lenvatinib has shown promising antitumor activity and a manageable safety profile in patients with unresectable HCC not amenable to TACE in the phase 1b study KEYNOTE-524 study (Eisai Study 116; NCT03006926) [28].